clinical trial · NCT06976203
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb·phase3·recruiting·n = 586
Alzheimer's DiseaseKarXTKarX-ECPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
started
Jul 21, 2025
primary completion
Sep 11, 2028
completion
Feb 23, 2029
last updated
Mar 31, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol